Physician profile
Lauren Rigg
NPI 1427583962
$4,129.63
in general payments reported to CMS, 2019-2025
20 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.12 · 2021: $85.23 · 2022: $612 · 2023: $1,012 · 2024: $869 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,243 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,242.61 |
| Education | $151.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,149.31 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $771.09 | 2022-2025 | Dupixent |
| Genzyme Corporation | $569.37 | 2022-2025 | |
| Glaxosmithkline, LLC. | $332.73 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Alk-Abello, INC | $194.14 | 2020-2022 | |
| Ars Pharmaceuticals Operations, INC. | $152.56 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $149.02 | 2022-2025 | Takhzyro, Eohilia, Hyqvia |
| Amgen INC. | $138.34 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $128.30 | 2024-2025 | |
| Optinose US, INC. | $118.45 | 2022-2024 | |
| Csl Behring | $106.12 | 2025 | Hizentra, Andembry |
| Grifols USA, LLC | $101.01 | 2022-2023 | Prolastin-C Liquid |
| Biocryst US Sales Co., LLC | $47.91 | 2022-2023 | Orladeyo |
| Lilly USA, LLC | $38.11 | 2025 | Ebglyss |
| Covis Pharma Gmbh | $36.73 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $21.61 | 2023 | Adbry |
| Ionis Pharmaceuticals, INC. | $21.44 | 2025 | Donidalorsen |
| Genentech USA, INC. | $19.17 | 2023 | Xolair |
| Galderma Laboratories, L.P. | $17.26 | 2025 | Nemluvio |
| Pfizer INC. | $16.96 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Rigg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.